지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.7
- 수록면
- 740 - 751 (12page)
- DOI
- 10.4093/dmj.2023.0189
이용수
초록· 키워드
오류제보하기
Background: We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis).Methods: A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination.Results: A composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography- liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH.Conclusion: Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
비알코올성 지방간 질환의 진단적 평가
대한내과학회지
2020 .10
-
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Clinical and Molecular Hepatology
2023 .02
-
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2023 .02
-
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Endocrinology and Metabolism
2020 .01
-
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Clinical and Molecular Hepatology
2023 .02
-
Serologic Biomarkers for Hepatic Fibrosis in Obese Children with Nonalcoholic Steatohepatitis
Pediatric Gastroenterology, Hepatology & Nutrition
2024 .07
-
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2021 .01
-
Recent advances in nonalcoholic fatty liver disease metabolomics
Clinical and Molecular Hepatology
2021 .10
-
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
-
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Clinical and Molecular Hepatology
2023 .02
-
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Endocrinology and Metabolism
2022 .02
-
Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease
Pediatric Gastroenterology, Hepatology & Nutrition
2015 .01
-
Recent research trends and updates on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2019 .01
-
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Clinical and Molecular Hepatology
2021 .01
-
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Clinical and Molecular Hepatology
2023 .02
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Journal of Yeungnam Medical Science
2019 .01
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
영남의대학술지
2019 .01
-
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Clinical and Molecular Hepatology
2023 .04
최근 본 자료
댓글(0)
0